1. Home
  2. OLPX vs GERN Comparison

OLPX vs GERN Comparison

Compare OLPX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olaplex Holdings Inc.

OLPX

Olaplex Holdings Inc.

HOLD

Current Price

$2.03

Market Cap

1.0B

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.75

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLPX
GERN
Founded
2014
1990
Country
United States
United States
Employees
N/A
229
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
OLPX
GERN
Price
$2.03
$1.75
Analyst Decision
Buy
Hold
Analyst Count
4
3
Target Price
$1.89
$2.17
AVG Volume (30 Days)
6.7M
18.7M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$422,960,000.00
N/A
Revenue This Year
$2.95
$26.91
Revenue Next Year
$3.39
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
0.07
N/A
52 Week Low
$0.99
$1.04
52 Week High
$2.04
$2.01

Technical Indicators

Market Signals
Indicator
OLPX
GERN
Relative Strength Index (RSI) 72.30 58.15
Support Level $1.20 $1.24
Resistance Level $2.04 $1.84
Average True Range (ATR) 0.01 0.10
MACD 0.01 0.02
Stochastic Oscillator 70.00 80.89

Price Performance

Historical Comparison
OLPX
GERN

About OLPX Olaplex Holdings Inc.

Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: